Compare Tango Therapeutics Inc. (TNGX) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs VF Corp — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while VF Corp trades at $16.38 (market cap $6.32B). The key difference: VF Corp is the larger of the two by market cap, and VF Corp pays a 2.24% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and VF Corp for 64 Days on average.
| TNGX | VFC | |
|---|---|---|
Market Cap | $3.75B | $6.32B |
Volume | 9,619,106 | 14,983,623 |
Sector | Health | Consumer Cyclical |
52-Week High | $32.90 | $21.55 |
52-Week Low | $7.50 | $12.62 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $2.77B | $10.60B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
VFC trades at $16.48, up 4.37% today, with a bullish technical signal and a consensus analyst price target of $18.33. Recent earnings show mixed results, with a Q4 2025 beat but Q1 and Q2 2026 misses. Revenue declined to $9.5B in 2025, with a net loss of $189.72M, though 2026 projects a return to profitability. The company maintains a strong gross margin of 54.97% but faces challenges from high debt and weak performance in its Vans brand.
The outlook is cautiously optimistic, supported by valuation discounts (P/S 0.67) and growth in outdoor brands, but execution risk on the Vans turnaround and high leverage pose significant threats. Near-term price action is buoyed by technical momentum, yet fundamental recovery hinges on sustained revenue improvement and debt reduction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
